Clinical practice guidelines for acute and chronic thyroiditis (excluding autoimmune thyroiditis)

Acute and chronic thyroid diseases are the most frequently detected disorders being second only to diabetes mellitus.
The World Health Organization points out that thyroid diseases’ incidence tends to grow every year. The present paper consists of clinical practice guidelines that consider etiology, clinical course, diagnostics and treatment of acute and chronic inflammatory thyroid diseases (except those of autoimmune type).
The clinical practice guidelines provide an important working tool for clinicians including specialty physicians and medical experts. Containing structured and concise information on the specific nosology, diagnostic methods and treatment tips these guidelines allow medical specialists to quickly resolve difficulties and choose the most efficient and personalized treatment (following strict principles of evidence-based medicine at the same time).
The clinical practice guidelines were drawn up by highly-skilled professional team of specialty physicians approved by the Expert Council of Russian Federation’s Health Department. These guidelines contain the most complete and up-to-date information required to diagnose acute and chronic thyroiditis, provide patient care and treatment.
The working group publishes the present paper in the professional journal dealing with endocrinology topics to improve healthcare quality and refine treatment of acute and chronic thyroiditis (autoimmune thyroiditis excluded). It is advisable to acquaint as many endocrinology and general (family) medicine specialists as possible with the full text of these clinical guidelines.

1. Sweeney L.B., Stewart C, Gaitonde DY. Thyroiditis: an integrated approach. Am Fam Physician. 2014;90(6):389-396.

2. Strakosch CR. Thyroiditis. Aust N Z J Med. 1986;16(1):91-100.

3. Shrestha RT, Hennessey J. Acute and Subacute, and Riedel’s Thyroiditis. [Internet] December 8, 2015. Available from: https://www.ncbi.nlm.nih.gov/books/NBK285553/

4. Fatourechi V, Aniszewski JP, Fatourechi GZE, et al. Clinical Features and Outcome of Subacute Thyroiditis in an Incidence Cohort: Olmsted County, Minnesota, Study. J Clin Endocrinol Metab. 2003;88(5):2100-2105. doi: https://doi.org/10.1210/jc.2002-021799

5. Asban A, Dream S, Lindeman B. Is Hyperthyroidism Diagnosed and Treated Appropriately in the United States? Adv Surg. 2019;53:117-129. doi: https://doi.org/10.1016/j.yasu.2019.04.007

6. Lebedeva EA, Iablonskaia IA, Bulgakova SV. Amiodarone-induced thyrotoxicosis: state of the art. Clin Exp Thyroidol. 2017;13(2):31-38. (In Russ.) doi: https://doi.org/10.14341/ket2017231-38

7. Barbesino G. Drugs Affecting Thyroid Function. Thyroid. 2010;20(7):763-770. doi: https://doi.org/10.1089/thy.2010.1635

8. Lazarus JH. Effect of lithium on the thyroid gland. In: Pharmacotherapeutics of the thyroid gland. Ed by Weetman AP, Grossman A. Berlin, Germany: Springer-Verlag, 1997, P. 207-218.

9. Heufelder AE, Hay ID. Evidence for autoimmune mechanisms in the evolution of invasive fibrous thyroiditis (Riedel’s struma). Clin Investig. 1994;72(10):788-793. doi: https://doi.org/10.1007/BF00180548.

10. Rizzo LF, Mana DL, Bruno OD. Non-autoimmune thyroiditis. Medicina (B Aires). 2014;74(6):481-492.

11. Melmed, Shlomo, Kenneth S, et al. Acute Infectious Thyroiditis. Willams Textbook of Endocrinology. Ed. by Henry M. Kronenberg. 11th ed. Philadelphia: Elsevier, 2008. P. 945-947.

12. Berger SA, Zonszein J, Villamena P, Mittman N. Infectious diseases of the thyroid gland. Rev Infect Dis. 1983;5:108-122.

13. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55:1-17.

14. Falhammar H, Wallin G, Calissendorff J. Acute suppurative thyroiditis with thyroid abscess in adults: clinical presentation, treatment and outcomes. BMC Endocr Disord. 2019;19(1):130. doi: https://doi.org/10.1186/s12902-019-0458-0

15. Dimos G, Pappas G, Akritidis N. Subacute thyroiditis in the course of novel H1N1 influenza infection. Endocrine. 2010;37(3):440-441. doi: https://doi.org/10.1007/s12020-010-9327-3

16. Volta C, Carano N, Street ME, Bernasconi S. Atypical Subacute Thyroiditis Caused by Epstein-Barr Virus Infection in a Three-Year-Old Girl. Thyroid. 2005;15(10):1189-1191. doi: https://doi.org/10.1089/thy.2005.15.1189

17. Bouillet B, Petit J-M, Piroth L, et al. A Case of Subacute Thyroiditis Associated with Primary HIV Infection. Am J Med. 2009;122(4):e5-e6. doi: https://doi.org/10.1016/j.amjmed.2008.11.010

18. Satoh M. Virus-like particles in the follicular epithelium of the thyroid from a patient with subacute thyroiditis (deQuervain’s). Acta Pathol Jpn. 1975;25:499-501.

19. Engkakul P, Mahachoklertwattana P, Poomthavorn P. de Quervain thyroiditis in a young boy following hand–foot–mouth disease. Eur J Pediatr. 2011;170(4):527-529. doi: https://doi.org/10.1007/s00431-010-1305-5

20. Stasiak M, Tymoniuk B, Stasiak B, Lewiński A. The Risk of Recurrence of Subacute Thyroiditis Is HLA-Dependent. Int J Mol Sci. 2019;20(5):1089. doi: https://doi.org/10.3390/ijms20051089

21. Stasiak M, Tymoniuk B, Michalak R, et al. Subacute Thyroiditis is Associated with HLA-B*18:01, -DRB1*01 and -C*04:01—The Significance of the New Molecular Background. J Clin Med. 2020;9(2):534. doi: https://doi.org/10.3390/jcm9020534

22. Bindra A, Braunstein GD. Thyroiditis. Am Fam Physician. 2006;73(10):1769-1776.

23. Kojima M, Nakamura S, Oyama T, et al. Cellular Composition of Subacute Thyroiditis. An Immunohistochemical Study of Six Cases. Pathol - Res Pract. 2002;198(12):833-837. doi: https://doi.org/10.1078/0344-0338-00344

24. Sviridenko NYu, Platonova NM, Molashenko NV. Endocrine aspects of amiodarone therapy in clinical practice (follow-up and treatment algorithm for patients with thyroid dysfunction). Rossiiskii kardiologicheskii zhurnal. 2012;2(94):63-71. (In Russ.)

25. Bartalena L, Bogazzi F, Chiovato L, et al. 2018 European Thyroid Association (ETA) Guidelines for the Management of AmiodaroneAssociated Thyroid Dysfunction. Eur Thyroid J. 2018;7(2):55-66. doi: https://doi.org/10.1159/000486957

26. Trohman RG, Sharma PS, McAninch EA, Bianco AC. Amiodarone and thyroid physiology, pathophysiology, diagnosis and management. Trends Cardiovasc Med. 2019;29(5):285-295. doi: https://doi.org/10.1016/j.tcm.2018.09.005

27. Steinke J, Borish L. 3. Cytokines and chemokines. J Allergy Clin Immunol. 2006;117(2):S441-S445. doi: https://doi.org/10.1016/j.jaci.2005.07.001

28. Bartolomé J, Rodríguez-Iñigo E, Quadros P, et al. Detection of hepatitis C virus in thyroid tissue from patients with chronic HCV infection. J Med Virol. 2008;80(9):1588-1594. doi: https://doi.org/10.1002/jmv.21269

29. Munshi N, Balasubramanian A, Koziel M, et al. Hepatitis C and Human Immunodeficiency Virus Envelope Proteins Cooperatively Induce Hepatocytic Apoptosis via an Innocent Bystander Mechanism. J Infect Dis. 2003;188(8):1192-1204. doi: https://doi.org/10.1086/378643

30. Balasubramanian A, Ganju RK, Groopman JE. Signal Transducer and Activator of Transcription Factor 1 Mediates Apoptosis Induced by Hepatitis C Virus and HIV Envelope Proteins in Hepatocytes. J Infect Dis. 2006;194(5):670-681. doi: https://doi.org/10.1086/505708

31. Balasubramanian A, Ganju RK, Groopman JE. Hepatitis C Virus and HIV Envelope Proteins Collaboratively Mediate Interleukin-8 Secretion through Activation of p38 MAP Kinase and SHP2 in Hepatocytes. J Biol Chem. 2003;278(37):35755-35766. doi: https://doi.org/10.1074/jbc.M302889200

32. Kibirige D, Luzinda K, Ssekitoleko R. Spectrum of lithium induced thyroid abnormalities: a current perspective. Thyroid Res. 2013;6(1):3. doi: https://doi.org/10.1186/1756-6614-6-3

33. Kraszewska A, Ziemnicka K, Jończyk-Potoczna K, Sowiński J, Rybakowski JK. Thyroid structure and function in long-term lithium-treated and lithium-naïve bipolar patients. Hum Psychopharmacol Clin Exp. July 2019. doi: https://doi.org/10.1002/hup.2708

34. Lazarus JH, Ludgate M, McGregor A et al. Lithium therapy induces autoimmune thyroid disease. In: Autoimmunity and the thyroid. Ed by Walfish PG, Wall JR, Volpe R. London: Academic Press, 1985. P. 319-320.

35. Kraszewska A, Ziemnicka K, Sowiński J, et al. No Connection between Long-Term Lithium Treatment and Antithyroid Antibodies. Pharmacopsychiatry. 2019;52(05):232-236. doi: https://doi.org/10.1055/a-0838-6062

36. Mizukami Y, Michigishi T, Nonomura A, Nakamura S, Noguchi M, Takazakura E. Histological features of the thyroid gland in a patient with lithium induced thyrotoxicosis. J Clin Pathol. 1995;48(6):582-584. doi: https://doi.org/10.1136/jcp.48.6.582

37. Lazarus JH. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23(6):723-733. doi: https://doi.org/10.1016/j.beem.2009.06.002

38. Li Y, Bai Y, Liu Z, et al. Immunohistochemistry of IgG4 can help subclassify Hashimoto’s autoimmune thyroiditis. Pathol Int. 2009;59(9):636-641. doi: https://doi.org/10.1111/j.1440-1827.2009.02419.x

39. Gosi SKY, Garla VV. Riedel Thyroiditis In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019.

40. Papi G, LiVolsi VA. Current Concepts on Riedel Thyroiditis. Pathol Patterns Rev. 2004;121(1):S50-S63. doi: https://doi.org/10.1309/NUU88VAFR9YEHKNA

41. Paes JE, Burman KD, Cohen J, et al. Acute Bacterial Suppurative Thyroiditis: A Clinical Review and Expert Opinion. Thyroid. 2010;20(3):247-255. doi: https://doi.org/10.1089/thy.2008.0146

42. Yolmo D, Madana J, Kalaiarasi R, et al. Retrospective case review of pyriform sinus fistulae of third branchial arch origin commonly presenting as acute suppurative thyroiditis in children. J Laryngol Otol. 2012;126(7):737-742. doi: https://doi.org/10.1017/S0022215112000898

43. Brook I. Microbiology and management of acute suppurative thyroiditis in children. Int J Pediatr Otorhinolaryngol. 2003;67(5):447-451. doi: https://doi.org/10.1016/S0165-5876(03)00010-7

44. Wasniewska M, Vigone MC, Cappa M, et al. Acute Suppurative Thyroiditis in Childhood: Spontaneous Closure of Sinus Pyriform Fistula May Occur Even Very Early. J Pediatr Endocrinol Metab. 2007;20(1):75-77. doi: https://doi.org/10.1515/JPEM.2007.20.1.75

45. Ogawa E, Katsushima Y, Fujiwara I, Iinuma K. Subacute Thyroiditis in Children: Patient Report and Review of the Literature. J Pediatr Endocrinol Metab. 2003;16(6):897-900. doi: https://doi.org/10.1515/JPEM.2003.16.6.897.

46. Nishihara E, Ohye H, Amino N, et al. Clinical Characteristics of 852 Patients with Subacute Thyroiditis before Treatment. Intern Med. 2008;47(8):725-729. doi: https://doi.org/10.2169/internalmedicine.47.0740

47. Alfadda AA, Sallam RM, Elawad GE, AlDhukair H, Alyahya MM. Subacute Thyroiditis: Clinical Presentation and Long Term Outcome. Int J Endocrinol. 2014;2014:1-7. doi: https://doi.org/10.1155/2014/794943

48. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003;348(26):2646-2655. doi: https://doi.org/10.1056/NEJMra021194.

49. Ruzieh M, Moroi MK, Aboujamous NM, et al. Meta-Analysis Comparing the Relative Risk of Adverse Events for Amiodarone Versus Placebo. Am J Cardiol. 2019;124(12):1889-1893. doi: https://doi.org/10.1016/j.amjcard.2019.09.008

50. Morgunova TB, Rechetnik NA, Fadeyev VV. Citokineinduced thyroid disorders. Clin Exp Thyroidol. 2011;7(1):19-28. (In Russ.) doi: https://doi.org/10.14341/ket20117119-28

51. Bini EJ, Mehandru S. Incidence of Thyroid Dysfunction During Interferon Alfa-2b and Ribavirin Therapy in Men With Chronic Hepatitis C. Arch Intern Med. 2004;164(21):2371-2376. doi: https://doi.org/10.1001/archinte.164.21.2371

52. Chang Y-K, Tseng Y-T, Chen K-H, Chen K-T. Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan. BMC Endocr Disord. 2019;19(1):36. doi: https://doi.org/10.1186/s12902-019-0362-7

53. Kirov G, Tredget J, John R, Owen MJ, Lazarus JH. A crosssectional and a prospective study of thyroid disorders in lithium-treated patients. J Affect Disord. 2005;87(2-3):313-317. doi: https://doi.org/10.1016/j.jad.2005.03.010

54. Lazarus JH. The Effects of Lithium Therapy on Thyroid and Thyrotropin-Releasing Hormone. Thyroid. 1998;8(10):909-913. doi: https://doi.org/10.1089/thy.1998.8.909

55. Brownlie BEW, Turner JG. Lithium associated thyrotoxicosis. Clin Endocrinol (Oxf ). 2011;75(3):402-403. doi: https://doi.org/10.1111/j.1365-2265.2011.04048.x

56. Taous A, Islam MS. Thyroiditis: differential diagnosis and management. Bangladesh J Otorhinolaryngol. 1970;16(1):48-53. doi: https://doi.org/10.3329/bjo.v16i1.5781

57. Goichot B, Caron P, Landron F, Bouée S. Clinical presentation of hyperthyroidism in a large representative sample of outpatients in France: relationships with age, aetiology and hormonal parameters. Clin Endocrinol (Oxf ). 2016;84(3):445-451. doi: https://doi.org/10.1111/cen.12816

58. Benbassat CA, Olchovsky D, Tsvetov G, Shimon I. Subacute thyroiditis: Clinical characteristics and treatment outcome in fifty-six consecutive patients diagnosed between 1999 and 2005. J Endocrinol Invest. 2007;30(8):631-635. doi: https://doi.org/10.1007/BF03347442

59. Keely EJ. Postpartum thyroiditis: an autoimmune thyroid disorder which predicts future thyroid health. Obstet Med. 2011;4(1):7-11. doi: https://doi.org/10.1258/om.2010.100041

60. Mincer DL, Jialal I. Hashimoto Thyroiditis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. 2020 Aug 10.

61. Girgis CM, Champion BL, Wall JR. Current Concepts in Graves’ Disease. Ther Adv Endocrinol Metab. 2011;2(3):135-144. doi: https://doi.org/10.1177/2042018811408488

62. Endokrinologiya. Natsional’noe rukovodstvo. Ed. by Dedov II, Mel’nichenko GA. Moscow: GEOTAR-Media, 2016. P. 638-640. (In Russ.)

63. Bonnyns M, Vanhaelst L, Bastenie PA. Asymptomatic Atrophic Thyroiditis. Horm Res. 1982;16(5):338-344. doi: https://doi.org/10.1159/000179522

64. Veit F, Graf D, Momberger S, et al. Papillary Thyroid Cancer and Coexisting Autoimmune Thyroiditis. Horm Metab Res. 2017;49(11):869-872. doi: https://doi.org/10.1055/s-0043-120922

65. Matesa-Anić D, Matesa N, Dabelić N, Kusić Z. Coexistence of papillary carcinoma and Hashimoto’s thyroiditis. Acta Clin Croat. 2009;48(1):9-12.

66. Gopalakrishnan S, Marwaha RK. Juvenile Autoimmune Thyroiditis. J Pediatr Endocrinol Metab. 2007;20(9): 961-970. doi: https://doi.org/10.1515/JPEM.2007.20.9.961

67. Rizzo LFL, Mana DL, Serra HA. Drug-induced hypothyroidism. Medicina (B Aires). 2017;77(5):394-404.

68. Furlow B. Immunotherapy Patients Should Be Monitored for Destructive Thyroiditis. ATA Thyroid Cancer. 2016.

69. Falhammar H, Juhlin CC, Barner C, et al. Riedel’s thyroiditis: clinical presentation, treatment and outcomes. Endocrine. 2018;60(1):185-192. doi: https://doi.org/10.1007/s12020-018-1526-3

70. Mel’nichenko GA, Larina II. Syndrome of thyrotoxicosis. Differential diagnosis and treatment. Ter Arkh. 2018;90(10):4-13. (In Russ.) doi: https://doi.org/10.26442/terarkh201890104-13

71. Al-Dajani N, Wootton SH. Cervical Lymphadenitis, Suppurative Parotitis, Thyroiditis, and Infected Cysts. Infect Dis Clin North Am. 2007;21(2):523-541. doi: https://doi.org/10.1016/j.idc.2007.03.004

72. Kale S, Kumar A, David V. Thyroid abscess an acute emergency. Eur Arch Oto-Rhino-Laryngology. 2004;261(8):456-458. doi: https://doi.org/10.1007/s00405-003-0715-7

73. Frates MC, Marqusee E, Benson CB, Alexander EK. Subacute Granulomatous (de Quervain) Thyroiditis. J Ultrasound Med. 2013;32(3):505-511. doi: https://doi.org/10.7863/jum.2013.32.3.505

74. Woolf PD. Transient Painless Thyroiditis with Hyperthyroidism: A Variant of Lymphocytic Thyroiditis? Endocr Rev. 1980;1(4):411-420. doi: https://doi.org/10.1210/edrv-1-4-411

75. Devereaux D, Tewelde SZ. Hyperthyroidism and Thyrotoxicosis. Emerg Med Clin North Am. 2014;32(2):277-292. doi: https://doi.org/10.1016/j.emc.2013.12.001

76. Boelaert K, Torlinska B, Holder RL, Franklyn JA. Older Subjects with Hyperthyroidism Present with a Paucity of Symptoms and Signs: A Large Cross-Sectional Study. J Clin Endocrinol Metab. 2010;95(6):2715-2726. doi: https://doi.org/10.1210/jc.2009-2495

77. Carlé A, Knudsen N, Pedersen IB, et al. Determinants of serum T4 and T3 at the time of diagnosis in nosological types of thyrotoxicosis: a population-based study. Eur J Endocrinol. 2013;169(5):537-545. doi: https://doi.org/10.1530/EJE-13-0533

78. Koh LKH, Greenspan FS, Yeo PPB. Interferon-α Induced Thyroid Dysfunction: Three Clinical Presentations and a Review of the Literature. Thyroid. 1997;7(6):891-896. doi: https://doi.org/10.1089/thy.1997.7.891

79. Fatourechi MM, Hay ID, McIver B, et al. Invasive Fibrous Thyroiditis (Riedel Thyroiditis): The Mayo Clinic Experience, 1976–2008. Thyroid. 2011;21(7):765-772. doi: https://doi.org/10.1089/thy.2010.0453

80. Lee IS, Lee JU, Lee K-J, et al. Painful immunoglobulin G4-related thyroiditis treated by total thyroidectomy. Korean J Intern Med. 2016;31(2):399-402. doi: https://doi.org/10.3904/kjim.2014.283

81. Li Y, Nishihara E, Hirokawa M, et al. Distinct Clinical, Serological, and Sonographic Characteristics of Hashimoto’s Thyroiditis Based with and without IgG4-Positive Plasma Cells. J Clin Endocrinol Metab. 2010;95(3):1309-1317. doi: https://doi.org/10.1210/jc.2009-1794

82. Erdem N, Erdogan M, Ozbek M, et al. Demographic and clinical features of patients with subacute thyroiditis: Results of 169 patients from a single University Center in Turkey. J Endocrinol Invest. 2007;30(7):546-550. doi: https://doi.org/10.1007/BF03346347

83. Ahmed S, Van Gelder I, Wiesfeld A, et al. Determinants and outcome of amiodarone-associated thyroid dysfunction. Clin Endocrinol (Oxf ). 2011;75(3):388-394. doi: https://doi.org/10.1111/j.1365-2265.2011.04087

84. Martino E, Macchia E, Aghini-Lombardi F, et al. Is humoral thyroid autoimmunity relevant in amiodarone iodine-induced thyrotoxicosts (AIIT)? Clin Endocrinol (Oxf ). 1986;24(6):627-633. doi: https://doi.org/10.1111/j.1365-2265.1986.tb01658.x

85. Tomisti L, Urbani C, Rossi G, et al. The presence of antithyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodaroneinduced thyrotoxicosis. J Endocrinol Invest. 2016;39(5):585-591. doi: https://doi.org/10.1007/s40618-015-0426-0

86. Tomer Y, Menconi F. Interferon induced thyroiditis. Best Pract Res Clin Endocrinol Metab. 2009;23(6):703-712. doi: https://doi.org/10.1016/j.beem.2009.07.004

87. Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: Toward a new classification. Hepatology. 2006;43(4):661-672. doi: https://doi.org/10.1002/hep.21146

88. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. doi: https://doi.org/10.1089/thy.2016.0229

89. Hennessey JV. Riedel’s Thyroiditis: A Clinical Review. J Clin Endocrinol Metab. 2011;96(10):3031-3041. doi: https://doi.org/10.1210/jc.2011-0617

90. Cappelli C, Pirola I, Gandossi E, et al. Ultrasound findings of subacute thyroiditis: a single institution retrospective review. Acta radiol. 2014;55(4):429-433. doi: https://doi.org/10.1177/0284185113498721

91. Ruchala M, Szczepanek-Parulska E, Zybek A, et al. The role of sonoelastography in acute, subacute and chronic thyroiditis: a novel application of the method. Eur J Endocrinol. 2012;166(3):425-432. doi: https://doi.org/10.1530/EJE-11-0736

92. Bogazzi F, Martino E, Dell’Unto E, et al. Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis. J Endocrinol Invest. 2003;26:635-640. doi: https://doi.org/10.1007/BF03347021

93. Eaton SEM, Euinton HA, Newman CM, et al. Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin Endocrinol (Oxf). 2002;56(1):33-38. doi: https://doi.org/10.1046/j.0300-0664.2001.01457.x

94. Theodoraki A, Vanderpump MPJ. Thyrotoxicosis associated with the use of amiodarone: the utility of ultrasound in patient management. Clin Endocrinol (Oxf ). 2016;84(2):172-176. doi: https://doi.org/10.1111/cen.12988

95. Pattison DA, Westcott J, Lichtenstein M, et al. Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium-99m sestamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosis. Nucl Med Commun. 2015;36(4):356-362. doi: https://doi.org/10.1097/MNM.0000000000000260

96. Censi S, Bodanza V, Manso J, et al. Amiodarone-Induced Thyrotoxicosis. Clin Nucl Med. 2018;43(9):655-662. doi: https://doi.org/10.1097/RLU.0000000000002207

97. Piga M, Cocco MC, Serra A, et al. The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. Eur J Endocrinol. 2008;159(4):423-429. doi: https://doi.org/10.1530/EJE-08-0348

98. Krupińska J, Wawrzynowicz-Syczewska M, Urbanowicz W, et al. The influence of interferon alpha on the induction of autoimmune thyroiditis in patients treated for chronic viral hepatitis type C. Endokrynol Pol. 2011;62(6):517-522

99. Papi G, Corrado S, Cesinaro AM, et al. Riedel’s thyroiditis: clinical, pathological and imaging features. Int. J. Clin. Pract. 2002;56(1):65-67.

100. Ozgen A, Cila A. Riedel’s thyroiditis in multifocal fibrosclerosis: CT and MR imaging findings. AJNR Am J Neuroradiol. 2000;21(2):320-321.

101. Yakh’ya ADM. Klinicheskie osobennosti techeniya podostrogo tireoidita i sovremennye metody ego lecheniya. Mezhdunarodnyi endokrinologicheskii zhurnal. 2011;1(33):122-127. (In Russ.)

102. Izumi Y, Hidaka Y, Tada H, et al. Simple and practical parameters for differentiation between destruction-induced thyrotoxicosis and Graves’ thyrotoxicosis. Clin Endocrinol (Oxf ). 2002;57(1):51-58. doi: https://doi.org/10.1046/j.1365-2265.2002.01558.x

103. Prajapati S, Hernandez-Prera JC. Putting All the Pieces Together: Clinical, Macroscopic and Microscopic Characteristics of Subacute Thyroiditis. Head Neck Pathol. 2019;13(2):231-234. doi: https://doi.org/10.1007/s12105-018-0890-x

104. Stasiak M, Michalak R, Lewinski A. Thyroid primary and metastatic malignant tumours of poor prognosis may mimic subacute thyroiditis - time to change the diagnostic criteria: case reports and a review of the literature. BMC Endocr Disord. 2019;19(1):86. doi: https://doi.org/10.1186/s12902-019-0415-y.

105. Koirala KP. Treatment of Acute Painful Thyroiditis with Low Dose Prednisolone: A Study on Patients from Western Nepal. J Clin DIAGNOSTIC Res. 2015;9(9):1-3. doi: https://doi.org/10.7860/JCDR/2015/14893.6427

106. Few J, Thompson NW, Angelos P, et al. Riedel’s thyroiditis: Treatment with tamoxifen. Surgery. 1996;120(6):993-999. doi: https://doi.org/10.1016/S0039-6060(96)80045-6

107. Chrobok V, Celakovsky P, Nunez-Fernandez D, Simakova E. Acute purulent thyroiditis with retropharyngeal and retrotracheal abscesses. J Laryngol Otol. 2000;114(2):151-153. doi: https://doi.org/10.1258/0022215001904941

108. Mollar-Puchades MA, Cámara-Gómez R, Pérez-Guillen V, et al. Thyroid Hematoma and Infectious Thyroiditis After a Neck Injury. Thyroid. 2006;16(4):421-422. doi: https://doi.org/10.1089/thy.2006.16.421

109. McLaughlin SA, Smith SL, Meek SE. Acute Suppurative Thyroiditis Caused by Pasteurella multocida and Associated with Thyrotoxicosis. Thyroid. 2006;16(3):307-310. doi: https://doi.org/10.1089/thy.2006.16.307

110. Agarwal A, Mishra SK, Sharma AK. Acute suppurative thyroiditis with demonstrable distant primary focus: a report of two cases. Thyroid. 1998;8:399-401.

111. Kim KH, Sung M-W, Oh SH, et al. Pyriform Sinus Fistula: Management with Chemocauterization of the Internal Opening. Ann Otol Rhinol Laryngol. 2000;109(5):452-456. doi: https://doi.org/10.1177/000348940010900503

112. Miyauchi A, Inoue H, Tomoda C, Amino N. Evaluation of Chemocauterization Treatment for Obliteration of Pyriform Sinus Fistula as a Route of Infection Causing Acute Suppurative Thyroiditis. Thyroid. 2009;19(7):789-793. doi: https://doi.org/10.1089/thy.2009.0015

113. Schneider R, Randolph GW, Dionigi G, et al. International neural monitoring study group guideline 2018 part I: Staging bilateral thyroid surgery with monitoring loss of signal. Laryngoscope. 2018;128(6):S1-S17. doi: https://doi.org/10.1002/lary.27359

114. Wu C-W, Dionigi G, Barczynski M, et al. International neuromonitoring study group guidelines 2018: Part II: Optimal recurrent laryngeal nerve management for invasive thyroid cancer-incorporation of surgical, laryngeal, and neural electrophysiologic data. Laryngoscope. 2018;128(6):S18-S27. doi: https://doi.org/10.1002/lary.27360

115. Qari FA, Maimani AA. Subacute thyroiditis in Western Saudi Arabia. Saudi Med J. 2005;26(4):630-633.

116. Raj R, Yada S, Jacob A, et al. Fever of Unknown Origin as a Sole Presentation of Subacute Thyroiditis in an Elderly Patient: A Case Report with Literature Review. Case Rep Endocrinol. 2018;2018:1-8. doi: https://doi.org/10.1155/2018/5041724

117. Kubota S, Nishihara E, Kudo T, et al. Initial Treatment with 15 mg of Prednisolone Daily Is Sufficient for Most Patients with Subacute Thyroiditis in Japan. Thyroid. 2013;23(3):269-272. doi: https://doi.org/10.1089/thy.2012.0459

118. Tagami T, Yambe Y, Tanaka T, et al. Short-Term Effects of ^|^beta;-adrenergic Antagonists and Methimazole in New-Onset Thyrotoxicosis Caused by Graves’ Disease. Intern Med. 2012;51(17):2285-2290. doi: https://doi.org/10.2169/internalmedicine.51.7302

119. Samuels MH. Subacute, Silent, and Postpartum Thyroiditis. Med Clin North Am. 2012;96(2):223-233. doi: https://doi.org/10.1016/j.mcna.2012.01.003

120. Sato J, Uchida T, Komiya K, et al. Comparison of the therapeutic effects of prednisolone and nonsteroidal anti-inflammatory drugs in patients with subacute thyroiditis. Endocrine. 2017;55(1):209-214. doi: https://doi.org/10.1007/s12020-016-1122-3

121. Arao T, Okada Y, Torimoto K, et al. Prednisolone Dosing Regimen for Treatment of Subacute Thyroiditis. J UOEH. 2015;37(2):103-110. doi: https://doi.org/10.7888/juoeh.37.103

122. Xu S, Jiang Y, Jia A, et al. Comparison of the therapeutic effects of 15 mg and 30 mg initial dosage of prednisolone daily in patients with subacute thyroiditis: protocol for a multicenter, randomized, open, parallel control study. Trials. 2020;21(1):418. doi: https://doi.org/10.1186/s13063-020-04337-8

123. Stasiak M, Michalak R, Stasiak B, Lewiński A. Time-Lag Between Symptom Onset and Diagnosis of Subacute Thyroiditis — How to Avoid the Delay of Diagnosis and Unnecessary Overuse of Antibiotics. Horm Metab Res. 2020;52(1):32-38. doi: https://doi.org/10.1055/a-1033-7524

124. Mazza E, Quaglino F, Suriani A, et al. Thyroidectomy for Painful Thyroiditis Resistant to Steroid Treatment: Three New Cases with Review of the Literature. Case Rep Endocrinol. 2015;2015:1-7. doi: https://doi.org/10.1155/2015/138327

125. Martino E, Aghini-Lombardi F, Mariotti S, et al. Amiodarone iodine-induced hypothyroid-ism: risk factors and followup in 28 cases. Clin Endocrinol (Oxf ). 1987;26(2):227-237. doi: https://doi.org/10.1111/j.1365-2265.1987.tb00781.x

126. Martino E, Bartalena L, Bogazzi F, Braverman LE. The Effects of Amiodarone on the Thyroid. Endocr Rev. 2001;22(2):240-254. doi: https://doi.org/10.1210/edrv.22.2.0427

127. Stott DJ, Rodondi N, Kearney PM, et al. Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism. N Engl J Med. 2017;376(26):2534-2544. doi: https://doi.org/10.1056/NEJMoa1603825

128. Huber G, Staub J-J, Meier C, et al. Prospective Study of the Spontaneous Course of Subclinical Hypothyroidism: Prognostic Value of Thyrotropin, Thyroid Reserve, and Thyroid Antibodies. J Clin Endocrinol Metab. 2002;87(7):3221-3226. doi: https://doi.org/10.1210/jcem.87.7.867

129. Gøtzsche LSB-H, Boye N, Laurberg P, Andreasen F. Rat Heart Thyroxine 5ʼ-Deiodinase is Sensitively Depressed by Amiodarone. J Cardiovasc Pharmacol. 1989;14(6):836-841. doi: https://doi.org/10.1097/00005344-198912000-00006

130. Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med. 2005;118(7):706-714. doi: https://doi.org/10.1016/j.amjmed.2004.11.028

131. Wong R, Cheung W, Stockigt JR, Topliss DJ. Heterogeneity of amiodarone-induced thyrotoxicosis: evaluation of colour-flow Doppler sonography in predicting therapeutic response. Intern Med J. 2003;33(9-10):420-426. doi: https://doi.org/10.1046/j.1445-5994.2003.00463.x

132. Eskes SA, Endert E, Fliers E, et al. Treatment of Amiodarone-Induced Thyrotoxicosis Type 2: A Randomized Clinical Trial. J Clin Endocrinol Metab. 2012;97(2):499-506. doi: https://doi.org/10.1210/jc.2011-2390

133. Stan MN, Sathananthan M, Warnes CA, et al. Amiodarone-Induced Thyrotoxicosis in Adults with Congenital Heart Disease -Clinical Presentation and Response to Therapy. Endocr Pract. 2014;20(1):33-40. doi: https://doi.org/10.4158/EP13059.OR

134. Bogazzi F, Bartalena L, Tomisti L, et al. Continuation of Amiodarone Delays Restoration of Euthyroidism in Patients with Type 2 Amiodarone-Induced Thyrotoxicosis Treated with Prednisone: A Pilot Study. J Clin Endocrinol Metab. 2011;96(11):3374-3380. doi: https://doi.org/10.1210/jc.2011-1678

135. Maqdasy S, Batisse-Lignier M, Auclair C, et al. AmiodaroneInduced Thyrotoxicosis Recurrence After Amiodarone Reintroduction. Am J Cardiol. 2016;117(7):1112-1116. doi: https://doi.org/10.1016/j.amjcard.2016.01.003

136. Bogazzi F, Bartalena L, Martino E. Approach to the Patient with Amiodarone-Induced Thyrotoxicosis. J Clin Endocrinol Metab. 2010;95(6):2529-2535. doi: https://doi.org/10.1210/jc.2010-0180

137. Thiel A, Schott M. Treatment of Amiodarone-Induced Thyrotoxicosis Type 2: A Randomized Clinical Trial. Yearbook of Endocrinology. 2012;2012:151-153. doi: https://doi.org/10.1016/j.yend.2012.05.036

138. Krishnan A, Khan EG. Amiodarone induced thyrotoxicosis? type2. Endocr Abstr. March 2017. doi: https://doi.org/10.1530/endoabs.48.CB7

139. Bartalena L, Brogioni S, Grasso L, et al. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J Clin En-docrinol Metab. 1996;81(8):2930-2933. doi: https://doi.org/10.1210/jcem.81.8.8768854

140. Tomisti L, Materazzi G, Bartalena L, et al. Total Thyroidectomy in Patients with Amiodarone-Induced Thyrotoxicosis and Severe Left Ventricular Systolic Dysfunction. J Clin Endocrinol Metab. 2012;97(10):3515-3521. doi: https://doi.org/10.1210/jc.2012-1797

141. Kaderli R, Fahrner R, Christ E, et al. Total Thyroidectomy for Amiodarone-induced Thyrotoxicosis in the Hyperthyroid State. Exp Clin Endocrinol Diabetes. 2015;124(01):45-48. doi: https://doi.org/10.1055/s-0035-1565094

142. Houghton SG, Farley DR, Brennan MD, et al. Surgical Management of Amiodarone-associated Thyrotoxicosis: Mayo Clinic Experience. World J Surg. 2004;28(11):1083-1087. doi: https://doi.org/10.1007/s00268-004-7599-6

143. Gough J, Gough IR. Total Thyroidectomy for Amiodaroneassociated Thyrotoxicosis in Patients with Severe Cardiac Disease. World J Surg. 2006;30(11):1957-1961. doi: https://doi.org/10.1007/s00268-005-0673-x

144. Cappellani D, Papini P, Pingitore A, et al. Comparison Between Total Thyroidectomy and Medical Therapy for Amiodarone-Induced Thyrotoxicosis. J Clin Endocrinol Metab. 2020;105(1):242-251. doi: https://doi.org/10.1210/clinem/dgz041

145. Bogazzi F, Tomisti L, Ceccarelli C, Martino E. Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis: a cautionary note. Clin Endocrinol (Oxf ). 2010;72(1):133-134. doi: https://doi.org/10.1111/j.1365-2265.2009.03600.x

146. Czarnywojtek A, Czepczynski R, Ruchala M, et al. Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT). Neuro Endocrinol Lett. 2009;30(2):209-214.

147. Hermida JS, Tcheng E, Jarry G, et al. Radioiodine ablation of the thyroid to prevent recur-rence of amiodarone-induced thyrotoxicosis in patients with resistant tachyarrhythmias. Europace. 2004;6(2):169-174. doi: https://doi.org/10.1016/j.eupc.2003.11.002

148. Gursoy A, Tutuncu NB, Gencoglu A, et al. Radioactive iodine in the treatment of type-2 amiodarone-induced thyrotoxicosis. J Natl Med Assoc. 2008;100(6):716-719. doi: https://doi.org/10.1016/s0027-9684(15)31348-1

149. Lieber I, Ott M, Öhlund L, et al. Lithium-associated hypothyroidism and potential for reversibility after lithium discontinuation: Findings from the LiSIE retrospective cohort study. J Psychopharmacol. 2020;34(3):293-303. doi: https://doi.org/10.1177/0269881119882858

150. McClellan J, Kowatch R, Findling RL. Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(1):107-125. doi: https://doi.org/10.1097/01.chi.0000242240.69678.c4

151. Panwar V, Lassi K. Stable Bipolar Patient Switched to Mania following Clinical Doses of Prednisone. Case Rep Psychiatry. 2011;2011:1-2. doi: https://doi.org/10.1155/2011/797658

152. Nishihara E, Amino N, Ohye H, et al. Extent of hypoechogenic area in the thyroid is related with thyroid dysfunction after subacute thyroiditis. J Endocrinol Invest. 2009;32(1):33-36. doi: https://doi.org/10.1007/BF03345675

153. Saklamaz A. Is There a Drug Effect on the Development of Permanent Hypothyroidism in Subacute Thyroiditis? Acta Endocrinol. 2017;13(1):119-123. doi: https://doi.org/10.4183/aeb.2017.119